Delays or Discontinuation of Research and Development and Delays in Obtaining Regulatory Approval
First written in FY2024. 2 of 3 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2022: 20 of 40 companies on the "Worse" side.
28 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「However, development may be extended or discontinued if research and development does not proceed as planned, obtaining marketing approval takes longer than expected, or a new product fails to perform as expected, among other reasons.」
Delays or discontinuation of research and development and delays in obtaining approvals remain key risks. - FY2025RestatedAnnual report
「Development may be extended or discontinued if research and development does not proceed as planned, obtaining marketing approval takes longer than expected, or a new product fails to perform as expected, among other reasons.」
Delays or discontinuation of research and development and delays in obtaining approvals remain key risks. - FY2024First statedAnnual report
「Development may be extended or discontinued if research and development does not proceed as planned, obtaining marketing approval takes longer than expected, or a new product fails to perform as expected, among other reasons.」
The company discloses the possibility that additional investment may be required and research and development costs may not be recovered.